Let's Get Proof

The Canadian Outcome Scale for Minor Stroke (COSMOS): a much-needed, novel 7-point scale to assess more Individualized outcomes in patients with minor stroke (mRS is not sufficient). @StrokeAHA_ASA Kudos to @mayank_G0 @draravindganesh Salome and team. ahajournals.org/doi/10.1161/ST…

We have also created a free training and certification program for COSMOS to facilitate its adoption in future clinical trials and cohorts worldwide: letsgetproof.com/lgp/the-canadi… @letsgetproof 👨‍🏫👩‍🏫🌎🌍🌏

🚨 We created the Canadian Outcome Scale for Minor Stroke (COSMOS) to better capture the spectrum of good to poor outcomes in minor stroke. Here, we present COSMOS and its high inter-/intra-rater reliability:🇨🇦🇨🇦🇨🇦ahajournals.org/doi/abs/10.116… @mayank_G0 @nishita_singh3 @StrokeAHA_ASA

🚨 In this worldwide Practice Current survey of neurologists on mgmt of MCI, there was cautious optimism re: anti-amyloid therapies, with concerns about side effects but a general interest to prescribe: neurology.org/doi/10.1212/CP… @GrahamAMcLeod, Aaron Switzer, Eric Smith @DCNSNeuro

🚨In our latest blog post, Jaanya Lal discusses what happens in our brains when our immune system turns against us, “From Defence to Danger”: letsgetproof.com/blog/defence-t…

🚨🧠Reflections and comments on our study of brain frailty and stroke severity in @AANmember @GreenJournal @joachimfladt @DCNSNeuro neurology.org/doi/10.1212/WN… Thank you @NeurologyToday!

🚨 Multiple Sclerosis is a neuro disease for which med research has made major strides over the past decades. Check out our latest blog post from Arshdeep Bhullar on Clinical Manifestations, Diagnosis & Clinical Course of MS! (therapeutics post to follow) letsgetproof.com/blog/multiple-…

🚨What if you could get a measure of someone's atherosclerotic burden right from a plain CT scan? Our pilot study on Arterial Brain Calcium (ABC) volume- a marker of athero & future stroke risk on non-contrast CT- now out in @JSCVD2: sciencedirect.com/science/articl… @dianajyk @DCNSNeuro

🚨Frailty and Stroke 🧠- this @WorldStrokeOrg Scientific Statement emphasizes the importance of conducting stroke trials in frail populations to inform evidence-based care: journals.sagepub.com/doi/10.1177/17… Thanks @nr_evans for leading this work! @DrTerryQuinn @DorcasGandhi and many others

🚨Time for the stroke world to drop recertification & retraining requirements for NIHSS & mRS! Our systematic review found NO evidence of benefit from this endess exercise doi.org/10.1017/cjn.20… Led by Davis Maclean @UCalgaryMed w/ @dianajyk @SCouttsMD @DrRickSwartz @JournalCJNS

🚨 🧠Why do patients with occlusions in the same location present with very different neuro deficits? We find that brain frailty may be part of the answer, being associated with baseline stroke severity +NIHSS recovery trajectories neurology.org/doi/10.1212/WN… @GreenJournal @DCNSNeuro

🙏 for the opportunity to analyze the #TEMPO2 data with a sex disaggregated lens 👉♀️ were less likely to achieve baseline mRS than♂️ after TIA/minor stroke 👉⬆️ recanalization with TNK, but no clinical benefit @SCouttsMD @mihill68 @JAHA_AHA ahajournals.org/doi/epub/10.11…

🚨 Cherry picking of patients can be a major problem in acute stroke trials. @mayank_G0 and I discuss factors contributing to cherry picking (such as the What's In It For Us [WIIFU] problem) + how we might measure and mitigate it: ahajournals.org/doi/10.1161/ST… @DCNSNeuro @StrokeAHA_ASA

🚨 New blog post by student researcher Praveer Bal on Hypertension, the leading preventable cause of stroke and heart disease 📷letsgetproof.com/blog/hypertens…

🚨 New blog post by student researcher Praveer Bal on Hypertension, the leading preventable cause of stroke and heart disease 🧠🫀 Learn about the different forms of hypertension and how to treat it! letsgetproof.com/blog/hypertens…

🚨Can 24h NIHSS be a primary outcome for acute stroke RCTs? 24h NIHSS results aligned with 90d mRS in 84% of RCTs, but early NIHSS risks misclassifying 1/4 patients doi.org/10.1161/JAHA.1… @johanna_ospel @manonkappelhof @rosevmcd @mihill68 @mayank_G0 @StrokeAHA_ASA @DCNSNeuro

🚨In focus groups for ACT-GLOBAL, our ongoing stroke adaptive platform trial, patients & caregivers supported APT design but identified priorities re: execution to safeguard patient autonomy & safety doi.org/10.1159/000546… @bijoymenon @KargerPublisher @DCNSNeuro @georgeinstitute

🚨Check out the new blog post from rising undergrad researcher (and @AvenueMagazine Top 20 Under 20) Nikhil Srivalsan on "The Future of Nanomedicine: Tiny Solutions to Big Health Problems" letsgetproof.com/blog/the-futur…

🚨In this prespecified analysis of the AcT RCT, we examined safety & efficacy outcomes of thrombolysis with tenecteplase & alteplase in elderly patients. 23% mRS 0-1 among >=80y vs 43% <80y. No difference in sICH. ahajournals.org/doi/10.1161/ST… @nishita_singh3 @DCNSNeuro @bijoymenon